ArticleAddiction science & clinical practice2025
Buprenorphine and postpartum contraception utilization among people with opioid use disorder: a multi-state analysis.
Article in Addiction science & clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association between pregnancy intention and postpartum contraceptive interest among pregnant people with opioid use disorder.Journal of substance use and addiction treatment · 2026Article
- Correction: Buprenorphine and postpartum contraception utilization among people with opioid use disorder: a multi-state analysis.Addiction science & clinical practice · 2025Article
- Postpartum contraceptive plans and fulfillment for pregnant people experiencing incarceration with substance use histories.Women's health (London, England)Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
Abstract
backgroundThe postpartum period provides an opportunity for birthing people with opioid use disorder (OUD) to consider their future reproductive health goals. However, the relationship between the use of medication for opioid use disorder (MOUD) and contraception utilization is not well understood. We used multistate administrative claims data to compare contraception utilization rates among postpartum people with OUD initiating buprenorphine (BUP) versus no medication (psychosocial services receipt without MOUD (PSY)) in the United States (US).
methodsIn this retrospective cohort study, we analyzed data from the Merative™ MarketScan
resultsOur sample consisted of 11,118 postpartum people with OUD. Among those, 3,443 initiated BUP and 7,675 received PSY. By 90 days postpartum, 22.4% (n = 2,487) of the cohort were prescribed contraception (21.5% PSY vs. 24.3% BUP). Among these participants, most received LARC (41.0%), followed by female sterilization (27.3%), the contraceptive injection (17.3%), pills (8.6%), ring (4.7%), and patch (1.0%), Compared to people engaged in PSY, BUP receipt was associated with a greater use of prescribed contraceptive use by 90 days postpartum (adjusted relative risk [aRR] = 1.17[1.07-1.28]), including a modestly greater use of the patch, ring, and pills, (aRR = 1.13[1.08-1.18]), but a modestly lesser use of injection contraception (aRR = 0.95[0.91-0.99]). There was no relationship observed between BUP and LARC use (aRR = 1.00[0.95-1.04]) and female sterilization (aRR = 1.01[0.98-1.06]).
conclusionsOnly 22% of pregnant people with OUD in our cohort used effective or highly-effective postpartum contraception. BUP receipt during pregnancy, relative to PSY, was associated with modestly greater use of prescribed effective contraceptive methods but was not associated with greater use of provider-administered contraceptive methods, such as the contraceptive injection, LARC and female sterilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.